Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial - Grégoire Stalder; Madeleine Suffiotti; Amandine Segot; Alessandra Noto; Giuseppe Pantaleo; Olivier Spertini; Michel Obeid (Haematologica, 2022)